HE
Prostatype Genomics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Prostatype® (CE-marked IVD) | Prognostic risk stratification for localized prostate cancer | Commercial |
| Prostatype® US Market Access | Prognostic risk stratification for localized prostate cancer | Development/Regulatory |
| Clinical Validation Studies | Prostate cancer (various cohorts) | Clinical Research |
Leadership Team at Prostatype Genomics
FR
Fredrik Rickman
Chief Executive Officer
SG
Steve Gaal
President, US Operations
AK
Anders Koch
Chief Financial Officer
EB
Emelie Berglund
Chief Technology Officer
DG
Dr. Gerald Andriole
Chief Medical Officer
KS
Katarina Sjöberg
Head of RA and QA
AL
Anders Lundberg
Chairman of the Board
DM
Dr. Michael Häggman
Board Member
JD
Jörgen Dahlström
Board Member
MP
Mattias Prage
Board Member